Skip to main
ALLO

ALLO Stock Forecast & Price Target

ALLO Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Allogene Therapeutics is positioned for success, with a promising pipeline of genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. The recent results from the Phase 3 ALPHA3 trial demonstrate the effectiveness of their lead candidate, cema-cel, in achieving MRD-negative rates and a manageable safety profile in patients with MRD+ DLBCL. These results, combined with the potential market opportunity in the community setting and the company's focus on deliverability and access attributes, could position Allogene as a leader in the CAR-T space. While there are risks to achieving their price target, the early data suggests a favorable outcome for Allogene's lead candidate and the company's future success.

Bears say

Allogene Therapeutics is heavily reliant on partners for access to gene-editing technology and may face risks of partner termination, underscoring the company's financial instability in a heavily competitive CAR-T cell therapeutic market. Despite a well-funded current state, additional equity financing may be required, posing potential dilution risks for investors. Additional issues include clinical risk, including the inherent risk of CAR-T therapies, potential failure of clinical trials, and regulatory and commercial risks, which depend on timely approval from regulatory agencies.

ALLO has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allogene Therapeutics Inc (ALLO) Forecast

Analysts have given ALLO a Buy based on their latest research and market trends.

According to 10 analysts, ALLO has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allogene Therapeutics Inc (ALLO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.